US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

VanEck Biotech ETF

240.47

+6.432.75%

Post-market: 240.14-0.3266-0.14%19:30 EDT

Volume:10.88K

Turnover:2.60M

Market Cap:482.50M

PE:- -

High:240.47

Open:234.08

Low:234.08

Close:234.03

52wk High:246.55

52wk Low:171.63

Shares:2.01M

Float Shares:2.01M

Volume Ratio:0.89

T/O Rate:0.54%

Dividend:0.96

Dividend Rate:0.40%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Amgen (AMGN) Stock Could Be 39% Undervalued Following KRAS Market Growth

Simply Wall St.

Regeneron Pharmaceuticals (REGN) Gets A Fresh Look As Trial Wins And Sanofi Deal Feed Value Narrative

Simply Wall St.

11% Undervalued? Vertex Pharmaceuticals (VRTX) Following New ALYFTREK Data

Simply Wall St.

Revolution Medicines (RVMD) Starts Phase 3 RASolute 309, Is It Still A Bargain?

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/BBH"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BBH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBH\",,,,,undefined,":{"symbol":"BBH","market":"US","secType":"STK","nameCN":"VanEck Biotech ETF","latestPrice":240.4666,"timestamp":1791576000000,"preClose":234.0318,"halted":0,"volume":10884,"hourTrading":{"tag":"盘后","latestPrice":240.14,"preClose":240.4666,"latestTime":"19:30 EDT","volume":12,"amount":2883.9364,"timestamp":1791588606301,"change":-0.3266,"changeRate":-0.001358,"amplitude":0},"delay":0,"changeRate":0.027495408743598074,"floatShares":2006503,"shares":2006503,"eps":0,"marketStatus":"Market Closed","change":6.4348,"latestTime":"10-09 16:00:00 EDT","open":234.08,"high":240.4666,"low":234.08,"amount":2595064.39236,"amplitude":0.027289,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":234.0318,"sharesOutstanding":1976503,"nav":240.40394,"aum":484775263.27,"dividendRate":0.00399,"bidAskSpread":0.001167,"postHourTrading":{"tag":"盘后","latestPrice":240.14,"preClose":240.4666,"latestTime":"19:30 EDT","volume":12,"amount":2883.9364,"timestamp":1791588606301,"change":-0.3266,"changeRate":-0.001358,"amplitude":0},"volumeRatio":0.8922189170173007,"impliedVol":0.1795,"impliedVolPercentile":0.2191},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBH\",,,,,undefined,":{"symbol":"BBH","floatShares":2006503,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.8922189170173007,"shares":2006503,"dividePrice":0.9595,"high":240.4666,"amplitude":0.027289,"preClose":234.0318,"low":234.08,"week52Low":171.63,"pbRate":"--","week52High":246.55,"institutionHeld":0,"latestPrice":240.4666,"eps":0,"divideRate":0.00399,"volume":10884,"delay":0,"ttmEps":0,"open":234.08,"prevYearClose":189.2649,"prevWeekClose":237.4531,"prevMonthClose":244.575,"prevQuarterClose":244.575,"fiveDayClose":237.4531,"twentyDayClose":229.3922,"sixtyDayClose":206.2544},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BBH\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"BBH","amount":0.9565,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"VanEck Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2024-12-23","symbol":"BBH","amount":1.2517,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"VanEck Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-24","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-24"},{"date":"2023-12-18","symbol":"BBH","amount":0.7127,"announcedDate":"2023-12-15","type":"dividend","market":"US","newRecordDate":"2023-12-19","defaultRemindTime":1702909800000,"name":"VanEck Biotech ETF","recordDate":"2023-12-22","payableDate":"2023-12-19","currency":"USD","dateTimestamp":1702875600000,"payDate":"2023-12-22"},{"market":"US","date":"2022-12-19","symbol":"BBH","amount":0.7488,"defaultRemindTime":1671460200000,"name":"VanEck Biotech ETF","recordDate":"2022-12-23","payableDate":"2022-12-20","currency":"USD","type":"dividend","dateTimestamp":1671426000000},{"market":"US","date":"2021-12-20","symbol":"BBH","amount":0.3972,"defaultRemindTime":1640010600000,"name":"VanEck Vectors Biotech ETF","recordDate":"2021-12-27","payableDate":"2021-12-21","currency":"USD","type":"dividend","dateTimestamp":1639976400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BBH\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-19","recordDate":"2016-12-21","paymentDate":"2016-12-23","value":0.327,"currency":"USD"},{"executeDate":"2018-12-20","recordDate":"2018-12-21","paymentDate":"2018-12-27","value":0.006,"currency":"USD"},{"executeDate":"2019-12-23","recordDate":"2019-12-24","paymentDate":"2019-12-30","value":0.4724,"currency":"USD"},{"executeDate":"2020-12-21","recordDate":"2020-12-22","paymentDate":"2020-12-28","value":0.6079,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-27","value":0.3972,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BBH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BBH\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2674481743","title":"Amgen (AMGN) Stock Could Be 39% Undervalued Following KRAS Market Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2674481743","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674481743?lang=en_us&edition=fundamental","pubTime":"2026-10-11 19:28","pubTimestamp":1791718112,"startTime":"0","endTime":"0","summary":"Amgen has delivered a powerful run in recent years, and the question now is whether the current share price lines up with the cash flows that underpin the business. With the stock trading around recent highs, investors are asking how much of Amgen's future cash generation is already reflected in today's valuation.\n\nAmgen has returned 133.2% over the past 5 years, which puts real pressure on the numbers to show that the cash it can generate justifies that kind of long haul performance.\nThe...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/24816-card/1789038959684","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/24816-card/1789038959684"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amgn/amgen/news/amgen-amgn-stock-could-be-39-undervalued-following-kras-mark","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amgn/amgen/news/amgen-amgn-stock-could-be-39-undervalued-following-kras-mark","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE00B4R5TH58.HKD","BBH","PBE","BK4581","LU0058720904.USD","LU0289739699.SGD","LU0868494617.USD","LU1571399168.USD","SPHQ","IBB","AMGN","BK4566","IBBQ","SG9999001440.SGD","LU2242646821.SGD","BK4534","BK4599","DCF","IE00BJJMRZ35.SGD","LU1057294990.SGD","LU0122379950.USD","IE00BFTCPJ56.SGD","LU2089984988.USD","BK4588","IE0009355771.USD","LU2242652126.USD","BIB","IE0002141913.USD","IE00B2B36J28.USD","LU1061106388.HKD","LU0320765992.SGD","LU2112291526.USD","BK4533","LU1983299246.USD","LU0889565916.HKD","TBXU","IE00BJT1NW94.SGD","LU0109394709.USD","BK4585","PJP","LU2468319806.SGD","LU1023059063.AUD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674815517","title":"Regeneron Pharmaceuticals (REGN) Gets A Fresh Look As Trial Wins And Sanofi Deal Feed Value Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2674815517","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674815517?lang=en_us&edition=fundamental","pubTime":"2026-10-11 07:25","pubTimestamp":1791674706,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals (REGN) has landed a cluster of high profile updates in October 2026, from early ubamatamab and trevogrumab trial readouts to a larger immunology antibody alliance with Sanofi, backed by a US$1b upfront payment.\nAll of this is landing while Regeneron Pharmaceuticals trades at US$746.54, with the share price up over the past quarter but down over the year to date. The 1 year total shareholder return of 32.9% indicates that momentum may be building again as investors...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/33715-card/1789122008118","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/33715-card/1789122008118"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-pharmaceuticals-regn-gets-a-fresh-look-as-trial-wi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-pharmaceuticals-regn-gets-a-fresh-look-as-trial-wi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0058720904.USD","IBB","LU0053666078.USD","LU1917777945.USD","LU0114720955.EUR","LU2023250504.SGD","LU0823434583.USD","BK4588","SNYNF","LU2362541273.HKD","BK4139","LU0320765992.SGD","LU0109394709.USD","LU2468319806.SGD","LU2362540622.SGD","IBBQ","LU1974910355.USD","LU0823416689.USD","TBXU","LU0889565916.HKD","LU2106854487.HKD","BK4585","LU2237438978.USD","LU2362541513.USD","BK4007","LU0289739699.SGD","LU2324357040.USD","BBH","REGN","LU0882574055.USD","LU2089984988.USD","LU0823434740.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674889959","title":"11% Undervalued? Vertex Pharmaceuticals (VRTX) Following New ALYFTREK Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2674889959","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674889959?lang=en_us&edition=fundamental","pubTime":"2026-10-10 15:30","pubTimestamp":1791617441,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals (VRTX) just put fresh clinical data for ALYFTREK in front of cystic fibrosis specialists at the North American Cystic Fibrosis Conference, highlighting early pancreatic function recovery in some very young children.\nVertex Pharmaceuticals’ recent ALYFTREK data arrives while the share price has climbed 12.82% year to date and the 1-year total shareholder return of 25.08% points to solid momentum, with a 5.09% 90-day share price return suggesting that investors are...","market":"us","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/36235-card/1788967613256","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/36235-card/1788967613256"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/11-undervalued-vertex-pharmaceuticals-vrtx-following-new-aly","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/11-undervalued-vertex-pharmaceuticals-vrtx-following-new-aly","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0889565916.HKD","LU1585245621.USD","IDNA","IE00B19Z9Z06.USD","LU2362541513.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","IBB","BK4588","IE00BZ9MQY76.HKD","LU1093756168.USD","LU0823416689.USD","LU1069344957.HKD","LU0058720904.USD","LU2089984988.USD","LU2462157665.USD","VERX","VRTX","LU2456880835.USD","LU1093756325.SGD","LU2362541273.HKD","LU0757428866.USD","GNMX","IE0009355771.USD","BK4023","IE00B894F039.SGD","BBH","LU0289739699.SGD","IE00B19Z9P08.USD","BK4567","LU0109394709.USD","LU1559883803.SGD","BK4139","LU1674673428.USD","BIB","IBBQ","TBXU","LU2236285917.USD","LU2417539215.USD","BK4532","LU1778281490.HKD","PBE","LU0234570918.USD","LU0061475181.USD","LU1674673691.USD","IE0002270589.USD","LU0566484027.USD","IE00BJT1NW94.SGD","BK4585","LU0256863811.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674995828","title":"Revolution Medicines (RVMD) Starts Phase 3 RASolute 309, Is It Still A Bargain?","url":"https://stock-news.laohu8.com/highlight/detail?id=2674995828","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674995828?lang=en_us&edition=fundamental","pubTime":"2026-10-10 14:29","pubTimestamp":1791613755,"startTime":"0","endTime":"0","summary":"Why the RASolute 309 trial matters for Revolution Medicines\nRevolution Medicines (RVMD) has started treating patients in its RASolute 309 Phase 3 trial, testing RASONQUE with zoldonrasib as a first-line option for metastatic RAS G12D pancreatic cancer.\nThe study compares this combination against standard chemotherapy gemcitabine and nab paclitaxel, with progression free survival and overall survival as dual primary endpoints that investors will watch closely.\nRevolution Medicines sits at...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/revolution-medicines-rvmd-starts-phase-3-rasolute-309-is-it","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/revolution-medicines-rvmd-starts-phase-3-rasolute-309-is-it","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ONX","IE0009354923.USD","LU1978683503.SGD","LU0320765992.SGD","BK4512","LU1548497426.USD","BK4141","ONG","LU2360107325.USD","LU0348723411.USD","LU1720051017.SGD","IE00BJJMRZ35.SGD","LU1861219969.SGD","IE00BD6J9T35.USD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","CANC","LU1861220033.SGD","LU0724618433.USD","LU0124384867.USD","LU1861215975.USD","LU0109394709.USD","IDNA","PTH","IE0002141913.USD","IE00B2B36J28.USD","LU1854104046.USD","LU2357305700.SGD","LU1854103824.USD","BK4139","LU1720051108.HKD","LU2298322129.HKD","BK4605","IE00BZ199S13.USD","IE00BJT1NW94.SGD","LU1861214812.USD","RVMD","BK4585","ON","LU0889565916.HKD","IE00BFMHRM44.USD","BK4588","BBH","IE0009355771.USD","LU1983260115.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":50,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/BBH\",params:#limit:6,delay:false,,,undefined,":[]}}